Medicare Is Cleaning Up the FDA’s Mess on Biogen’s Alzheimer’s Drug

By clarifying what evidence it needs before it will pay for medicines like Aduhelm, health officials paved the way for improved drug innovation.

Leave a Reply

%d bloggers like this: